Cart
sales@molnova.com
Tepotinib hydrochloride(1 : x)
CAS No. 1103508-80-0
Tepotinib hydrochloride(1 : x)( —— )
Catalog No. M28794 CAS No. 1103508-80-0
Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 402 | In Stock |
|
| 5MG | 319 | In Stock |
|
| 10MG | 472 | In Stock |
|
| 25MG | 753 | In Stock |
|
| 50MG | 1051 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTepotinib hydrochloride(1 : x)
-
NoteResearch use only, not for human use.
-
Brief DescriptionTepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations.
-
DescriptionTepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations.(In Vitro):Tepotinib hydrochloride(1 : x) potently inhibits ABCB1 and ABCG2 efflux transporters, which was confirmed by molecular docking. In addition, Tepotinib hydrochloride(1 : x) inhibited several recombinant cytochrome P450 (CYP) isoforms with varying potency. Tepotinib hydrochloride(1 : x) synergistically reversed daunorubicin and mitoxantrone resistance in cells with ABCB1 and ABCG2 overexpression, respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
RecptorPAK1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1103508-80-0
-
Formula Weight529.04
-
Molecular FormulaC29H29ClN6O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.McCoull W, et al. Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors. ACS Med Chem Lett. 2016 Sep 14;7(12):1118-1123. eCollection 2016 Dec 8.
molnova catalog
related products
-
BMS 777607
BMS 777607 is a potent, selective, orally efficacious inhibitor of Met kinase with IC50 of 3.9 nM.
-
Ningetinib
Ningetinib (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
-
AMG-458
AMG-458 (AMG458) is a potent, selective, orally bioavailable c-Met inhibitor with Ki of 1.2 nM.
